2410127L17Rik Activators
Akt1 Activators are a diverse set of chemical compounds that indirectly promote the activity of Akt1 through multifaceted signaling mechanisms. Forskolin elevates intracellular cAMP and activates PKA, which may phosphorylate proteins that interact with Akt1 signaling, thereby enhancing Akt1's role in cell survival and metabolism. PMA stimulates PKC, which can phosphorylate members of the Akt1 pathway or create a conducive signaling environment for Akt1 activation. Ionomycin increases intracellular calcium, potentially activating CaMK and other calcium-responsive elements within Akt1-related pathways, leading to its functional enhancement. Conversely, LY294002, a PI3K inhibitor, can paradoxically upregulate Akt1 activity by mitigating negative feedback loops that ordinarily restrain Akt1 signaling.
RIKEN cDNA 2410127L17 gene product (2410127L17Rik) activation is intricately linked to the modulation of intracellular cyclic nucleotide levels, particularly cAMP and cGMP. Forskolin, known for its direct stimulation of adenylyl cyclase, raises cAMP levels and thereby activates protein kinase A (PKA). In turn, PKA may phosphorylate and enhance the activity of 2410127L17Rik, assuming it is a substrate. Similarly, 8-Bromo-cAMP, a stable cAMP analog, activates PKA, providing a persistent activation signal to 2410127L17Rik. Sildenafil and Zaprinast, through PDE5 inhibition, and Vinpocetine, a PDE1 inhibitor, elevate both cAMP and cGMP levels, which could activate PKA or PKG, leading to phosphorylation and potential activation of 2410127L17Rik. IBMX extends this effect by broadly inhibiting phosphodiesterases, resulting in a general increase in cyclic nucleotides, and thus creating a conducive environment for the activation of 2410127L17Rik by PKA or PKG.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, leading to their accumulation. This can enhance PKA and PKG pathway activity, indirectly upregulating pathways that may increase the functional activity of 2410127L17Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, which can activate calcium-dependent signaling pathways. This may indirectly enhance the activity of 2410127L17Rik by modulating the signaling cascades 2410127L17Rik is involved in. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator that can modulate signaling pathways by phosphorylating target proteins, potentially enhancing the activity of 2410127L17Rik through PKC-dependent signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts on its specific G protein-coupled receptors to activate intracellular signaling cascades that can lead to the functional enhancement of 2410127L17Rik by modulating the protein's role in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter signaling dynamics, potentially increasing the activity of 2410127L17Rik by affecting downstream signaling proteins and processes that are positively regulated by PI3K inhibition and are involved with the function of 2410127L17Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that can shift the balance of MAPK/ERK signaling, potentially increasing the functional activity of 2410127L17Rik through the altered signaling environment resulting from MAPK/ERK pathway inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can modify cellular responses by impacting p38 MAPK-dependent pathways. This may lead to an indirect enhancement of 2410127L17Rik's activity by altering the signaling pathways in which 2410127L17Rik is a participant. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels, indirectly enhancing the activity of 2410127L17Rik by activating calcium-dependent signaling pathways with which 2410127L17Rik is associated. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate is a kinase inhibitor that can modulate signal transduction pathways, potentially enhancing the activity of 2410127L17Rik by influencing pathways and proteins that regulate 2410127L17Rik's function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that can affect multiple signaling pathways. It may selectively enhance the activity of 2410127L17Rik by inhibiting kinases that negatively regulate pathways associated with 2410127L17Rik's function. | ||||||